GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (NAS:NEOG) » Definitions » EV-to-EBIT
中文

Neogen (Neogen) EV-to-EBIT : 46.75 (As of Apr. 25, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Neogen EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Neogen's Enterprise Value is $3,388.2 Mil. Neogen's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $72.5 Mil. Therefore, Neogen's EV-to-EBIT for today is 46.75.

The historical rank and industry rank for Neogen's EV-to-EBIT or its related term are showing as below:

NEOG' s EV-to-EBIT Range Over the Past 10 Years
Min: 18.62   Med: 42.64   Max: 269.68
Current: 46.75

During the past 13 years, the highest EV-to-EBIT of Neogen was 269.68. The lowest was 18.62. And the median was 42.64.

NEOG's EV-to-EBIT is ranked worse than
84.11% of 107 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.2 vs NEOG: 46.75

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Neogen's Enterprise Value for the quarter that ended in Feb. 2024 was $4,445.2 Mil. Neogen's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $72.5 Mil. Neogen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was 1.63%.


Neogen EV-to-EBIT Historical Data

The historical data trend for Neogen's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen EV-to-EBIT Chart

Neogen Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.28 50.76 60.77 41.00 130.37

Neogen Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.21 130.37 119.27 57.62 61.34

Competitive Comparison of Neogen's EV-to-EBIT

For the Diagnostics & Research subindustry, Neogen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neogen's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neogen's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neogen's EV-to-EBIT falls into.



Neogen EV-to-EBIT Calculation

Neogen's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3388.168/72.471
=46.75

Neogen's current Enterprise Value is $3,388.2 Mil.
Neogen's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neogen  (NAS:NEOG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Neogen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2024 ) =EBIT / Enterprise Value (Q: Feb. 2024 )
=72.471/4445.21852
=1.63 %

Neogen's Enterprise Value for the quarter that ended in Feb. 2024 was $4,445.2 Mil.
Neogen's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neogen EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Neogen's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Neogen (Neogen) Business Description

Traded in Other Exchanges
Address
620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.
Executives
William T Boehm director
Douglas Edward Jones officer: Vice President, CCO 620 LESHER PLACE, LANSING MI 48912
Jason Warren Lilly officer: Vice President 620 LESHER PLACE, LANSING MI 48912
James P Tobin director 620 LESHER PLACE, LANSING MI 48895
David H. Naemura officer: VP & CFO C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Amy M Rocklin officer: Chief Legal & Reg. Officer 620 LESHER PLACE, LANSING MI 48912
Steven J. Quinlan officer: VP & CFO 620 LESHER PLACE, LANSING MI 48912
Jeffrey D Capello director C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Aashima Gupta director C/O NEOGEN CORPORATION, 620 LESHER PLACE, LANSING MI 48912
John Edward Adent officer: Chief Executive Officer 822 7TH STREET, SUITE 740, GREELEY CO 80631
Darci L Vetter director 620 LESHER PLACE, LANSING MI 48912
Ronald D Green director 620 LESHER PLACE, LANSING MI 48912
James C Borel director 1007 MARKET STREET, WILMINGTON DE 19898
Terri A Morrical officer: General Manager
G Bruce Papesh director 726 APPLEGATE LANE, EAST LANSING MI 48823